Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Kura Oncology and Caspian Therapeutics outlined the development strategy for KO-7246, an oral menin inhibitor designed for diabetes, on October 13, 2026.
Maxus Mining completed a multi-project airborne geophysical survey program across six blocks at the Alturas, Hurley, Quarry, and Lotto Projects in British Columbia.
Canopy Growth's Smiths Falls facility received EU GMP certification for softgel manufacturing and primary packaging of softgels, oral liquids, and dried cannabis flower.
Natera and TransCode Therapeutics will collaborate on a Phase 2a trial of TTX-MC138 for colorectal cancer (CRC) patients with molecular residual disease (MRD).
Prelude Therapeutics has partnered with Lilly to evaluate PRT13722, a KAT6A selective degrader, in combination with Lilly’s Verzenio® and Inluriyo® in a Phase 1 trial for HR+/HER2- breast cancer.